Edgewise Therapeutics, Inc.

NASDAQ: EWTX · Healthcare · Biotechnology

PublicHQ Boulder, CO · BoulderCIK 0001710072Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 67DQ —GM —SS 60

v0.1 · 35/100 weight · pillars only

↑ Altman-Z, balance-sheet leverage · ↓ listing tenure, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$167.8M

Employees

127

as of 2026-09-08

Market cap

$4.6B

as of 2026-09-08

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$167.8M-$167.8M2025

Operating income-$191.4M-$191.4M2025

Total assets$552.6M$552.6M2025

Liabilities$30.3M$30.3M2025

Equity$522.3M$522.3M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Edgewise Therapeutics, Inc.’s financial profile?

Edgewise Therapeutics, Inc. earned -$167.8M in FY2025 net income.

Peers · Healthcare

Erasca, Inc.——Definium Therapeutics, Inc.——Celcuity Inc.——Dyne Therapeutics, Inc.——Enliven Therapeutics, Inc.——Veradermics, Incorporated——

Neighbors

Boulder →

Enliven Therapeutics, Inc.——Infleqtion Inc——Solid Power, Inc.$17.9M37D Gores Holdings XI, Inc.——Gloo Holdings, Inc.$94.7M31D CEA Industries Inc. Common Stock$26.4M65B

Key facts

CEOKevin Koch

SectorHealthcare

IndustryBiotechnology

HeadquartersBoulder, CO

ExchangeNASDAQ: EWTX

Employees127

IPO date2021-03-26

Latest filings

10-Q2026-08-06 8-K2026-08-06 8-K2026-07-13 8-K2026-06-05 8-K2026-06-01 10-Q2026-05-07 8-K2026-05-07 DEF 14A2026-04-23

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.